Sickle Cell DiseaseDrugPhase 2
What this study is
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
What's being tested
- Alendronate Sodium
Intervention · DRUG
Administer oral alendronate 70 mg once a week x 24 weeks to all study participants
Study details
- Official title
- A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
- Sponsor
- University of California, Davis
- Conditions
- Sickle Cell Disease · Sickle Cell Anemia · Osteonecrosis · Ischemic Necrosis · Avascular Necrosis
- Enrolling
- 30 people
- Starts
- 2026-03-09
- Est. completion
- 2027-12
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 80 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
You can't join if
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUC Davis Comprehensive Cancer Center
Sacramento, California, United States
- Leyla Y Teos, PhD · Contact916-460-2749lyteos@ucdavis.edu
- Oyebimpe O Adesina, MD, MS · Contact(916) 703-5166adesina@ucdavis.edu
- Oyebimpe O Adesina, MD, MS · Principal investigator
Recruiting
Study team
Sponsor
University of California, Davis
Study ID 1693339
Principal investigator
Oyebimpe O Adesina, MD, MS
UC Davis School of Medicine
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.